Wednesday, November 12, 2003 | Oncolink

Oncolink Features

Find My Cancer Drug

Adjuvant Multimodality with Gemcitabine versus 5-Fluorouracil in Pancreatic Cancer: Status of U.S. Intergroup Trial Faculty Disclosure: William F. Regine, M.D. Nothing to Disclose Presenter: William F. Regine, M.D. Affiliation: University of Maryland Even with potentially curative resection, 5 year survival for pancreatic cancer patients is less than...
Alimta and Oxaliplatin in Colorectal Cancer Faculty Disclosure: Howard S. Hochster, M.D. Lilly - Consultant AstraZeneca - Consultant This presentation by Dr Hochster includes discussion on the use of pemetrexed in the treatment of colorectal cancer which has not been approved by...
Bevacizumab (Avastin) in Colorectal Cancer Faculty Disclosure: Daniel Haller, M.D. Roche - Research Support, Consultant OSI - Research Support Pfizer - Research Support, Consultant This presentation by Dr. Haller discusses the use of bevacizumab in the treatment of colorectal...
Emerging Role of EGF (Epidermal Growth Factor) Receptor-Directed Therapy of Colon Cancer Faculty Disclosure: Howard S. Hochster, M.D. Lilly - Consultant AstraZeneca - Consultant In this presentation by Dr. Hochster there is discussion of cetuximab (C 225) and erlotinib (Tarceva) for the treatment of colorectal cancer which is...
Experience with decitabine in imatinib resistant CML Faculty Disclosure: Hagop M. Kantarjian, M.D. Supergen - Research Support In this presentation Dr. Kantarjian discusses the use of decitabine for the treatment of CML which has not been approved by the FDA. Presenter: Hagop Kantarjian, MD ...
High dose imatinib (Gleevac) in CML Faculty Disclosure: Hagop M. Kantarjian, M.D. Novartis - Research Support Supergen - Research Support Presenter: Hagop Kantarjian, MD Affiliation: M.D. Anderson Cancer Center The Philadelphia chromosome and the resultant bcr-abl oncogene...
Mini Allo Transplants for Lymphoma/CLL Faculty Disclosure: Edwin P. Alyea III, MD Nothing to Disclose Presenter: Edwin P. Alyea III, MD Affiliation: Dana Farber Institute Patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) typically have relatively prolonged...
Modulating IL-2 for Non-Hodgkins' Lymphoma (NHL) Faculty Disclosure: Michael A. Caligiuri, M.D. This presentation by Dr. Caligiuri discusses off-label use of IL-2 for the treatment of NHL. Presenter: Michael A. Caligiuri, M.D. Affiliation: James Cancer Hospital and Ohio State University ...
Patient-specific therapeutic vaccines for non-Hodgkin's lymphoma Faculty Disclosure: John M. Timmerman, M.D. The presentation by Dr Timmerman includes discussion of vaccine therapy that has not been approved by the FDA and the use of GM-CSF as an off-label indication. Presenter: John M. Timmerman, M.D. ...
PTK 787/ZK 222584: Clinical results with a novel angiogenesis inhibitor in colorectal cancer Faculty Disclosure: Peter J. O'Dwyer, M.D. Novartis - Research Support AstraZeneca - Consultant, Speakers Bureau Lilly - Consultant BMS - Consultant Bayer - Consultant, Speakers Bureau Sanofi - Consultant Cell Therapeutics -...
Treatment of Cancer-Related Anemia Faculty Disclosure: Janice Gabrilove, M.D. Amgen - Research Support Ortho Biotech - Research Support, Speakers Bureau Berlex - Speakers Bureau Presenter: Janice Gabrilove, M.D. Affiliation: Mt. Sinai Hospital Cancer-related anemia...